Osocimab, formerly known as BAY 1213790, represents a unique monoclonal protein currently experiencing clinical development for the management of various hematologic malignancies. This agent specifically targets CD38, https://ammariskg515178.activoblog.com/51985744/osocimab-a-deep-investigation-into-bay-1213790-and-its-promise